Characterization of chicken Nf2/merlin indicates regulatory roles in cell proliferation and migration.
Characterization of chicken Nf2/merlin indicates regulatory roles in cell proliferation and migration.
复制标题
鸡 Nf2/merlin 的表征表明其在细胞增殖和迁移中的调节作用。
DOI:
10.1002/dvdy.20002
复制
发表时间:
2004
期刊:
影响因子:
--
通讯作者:
Krull,CE
中科院分区:
文献类型:
--
作者:
Chen,Y;Gutmann,DH;Haipek,CA;Martinsen,BJ;Bronner-Fraser,M;Krull,CE
The neurofibromatosis 2 (NF2) tumor suppressor protein merlin, or schwannomin, functions as a negative growth regulator such that inactivating mutations inNf2predispose humans to tumors. In addition, merlin has a critical role during embryonic development.Nf2‐deficient mice die early during embryogenesis, with defects in gastrulation and extraembryonic tissues. To investigate the function ofNf2/merlin during embryonic development, we first identified the homologousNf2gene in chicken (cNf2) and examined the distribution of chicken merlin (c‐merlin) during myogenesis.cNf2encoded a full‐length mRNA of 1,770 nucleotides and a protein of 589 residues. C‐merlin shared high sequence homology and common protein motifs with vertebrate andDrosophilamerlins. In addition,cNF2functions as a negative growth regulator similar to human andDrosophilamerlin in vitro. In vivo, c‐merlin was expressed diffusely in the forming dermomyotome but down‐regulated in migratory muscle precursors in the forelimb. As muscle formed in the limb, c‐merlin expression was up‐regulated. As an initial examination of c‐merlin function during myogenesis, c‐merlin was ectopically expressed in muscle precursors and the effects on muscle development were examined. We show that ectopic merlin expression reduces the proliferation of muscle precursors as well as their ability to migrate effectively in limb mesoderm. Collectively, these results demonstrate that c‐merlin is developmentally regulated in migrating and differentiating myogenic cells, where it functions as a negative regulator of both muscle growth and motility. Developmental Dynamics 229:541–554, 2004. © 2004 Wiley‐Liss, Inc.